Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for unresectable recurrent or metastatic esophageal squamous cell carcinoma
CTR20181308Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by InnoCare Pharma. Started Dec 2018; status: active.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20181308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181308.